Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Inspecs shares slide as interim earnings fall, H2 outlook weakens

(Sharecast News) - Shares in eyewear manufacturer Inspecs slumped nearly 10% on Thursday after it posted a drop in interim earnings and flagged weaker-than-expected trading in early H2, citing ongoing tariff disruption, subdued consumer confidence, and reduced government spending in the US.

Inspecs said revenue for the six months ended 30 June fell to £97.6m, down from £100.6m a year earlier, while underlying earnings declined to £9.0m from £11.0m. Gross margin narrowed to 51.8% from 52.6%, and diluted underlying earnings per share dropped to 2.08p from 3.94p. Pre-tax profits were broadly flat at £2.4m.

The AIM-listed group also said its Chinese manufacturing operations continued to face delays due to US tariffs, while European trading was said to have remained sluggish. Net debt excluding leases rose by £700,000 to £23.6m, driven by deferred acquisition payments and funding for discontinued operations.

However, despite the weaker start to the second half, Inspecs said growth in its order book and planned cost savings were expected to support a stronger performance in the remainder of the year. It also reiterated full-year guidance for underlying EBITDA of £18.7m.

CEO Richard Peck said: "As a global eyewear business, we have experienced first-hand the widely reported macro-challenges, including ongoing tariff disruption and subdued consumer confidence. As a result, group sales in the first half are slightly behind last year.

"Based on the growth in our order books as at the end of August 2025 and planned increased cost savings the board has a reasonable expectation of meeting full year guidance. We continue to believe in the fundamental strengths of the business and the management team remains focused on the delivery of our medium-term targets."

As of 1030 BST, Inspecs shares had sunk 9.53% to 38.90p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.